In the past, strabismus (a disease that affects 3% of the population) had a highly subjective diagnostic system that depended heavily on the specialist. This measuring system was so subjective that it caused second operations to definitively correct strabismus.
BCN Innova, a spin-off company of SJD Barcelona Children's Hospital, has developed a device (GazeLab) that substantially improves the diagnosis and treatment of strabismus. Today, the number of second operations performed to achieve the expected outcome has been reduced.
The main benefits are:
- GazeLab allows for an objective examination with revolutionary precision that exceeds the prevailing model of subjective measurements conducted up to the present.
- It reduces the number of second operations by 50%, which are unnecessary surgeries.
- Company founded (2009): BCN Innova.
- Worldwide patent.
- Marketed since 2013.